SUPN analyst estimates
Supernus Pharmaceuticals (SUPN) analyst ratings, the average price target and its range, and every firm's latest call.
SUPN analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Feb 25, 2026 | Craig-Hallum | Supernus Pharmaceuticals (SUPN) PT Raised to $65 at TD Cowen | $65.00 |
| Dec 19, 2025 | Stifel Nicolaus | Supernus price target raised to $55 from $50 at Stifel | $55.00 |
| Oct 8, 2025 | Piper Sandler | Supernus upgraded to Overweight from Neutral at Piper Sandler | $65.00 |
| Sep 30, 2025 | Cantor Fitzgerald | Supernus price target raised to $63 from $46 at Cantor Fitzgerald | $63.00 |
| Aug 29, 2025 | Piper Sandler | Supernus price target raised to $40 from $36 at Piper Sandler | $40.00 |
| Jul 29, 2025 | Cantor Fitzgerald | Supernus upgraded to Overweight from Neutral at Cantor Fitzgerald | $42.00 |
| Sep 11, 2024 | Piper Sandler | Piper downgrades Supernus to Neutral on slower Qelbree growth | $36.00 |
| May 24, 2024 | Piper Sandler | Piper Sandler Reiterates Overweight Rating on Supernus Pharmaceuticals (SUPN) | $41.00 |
| Apr 8, 2024 | Stifel Nicolaus | Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor' | $38.00 |
| Apr 8, 2024 | Jefferies | Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830' | $40.00 |
- 2 firms rate SUPN: 1 buy, 1 hold, 0 sell.
Updated 2026-11-02 17:13 UTC